drugset / Trial / NCT07058545
A Study of CJC-1134-PC Injection in Antidiabetic Treatment-naive Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
Phase 3
Completed
474 enrolled
Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of CJC-1134-PC Injection Administered Once Weekly in Antidiabetic Treatment-naive Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
Timeline
- Start
- 2021-04-16
- Primary completion
- 2023-02-20
- Completion
- 2023-02-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CJC-1134-PC | Unknown | 2 mg | — |